Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Japan / NCT07787182
Starting soon Phase 1

A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

NCT07787182 · tracked via the Priya Life Science Japan tracker
Sponsor
Eli Lilly and Company
Phase
Phase 1
Started
2026-09
Last updated
2026-09-22

Condition(s) studied

Healthy VolunteersAlzheimer DiseaseAmyloidPlaque, Amyloid

Investigational drug(s) / intervention(s)

LY4405094 →LY4405094 →PlaceboPlaceboFlorbetapir F18Florbetaben F 18

LY4405094: Administered intravenously (IV)

LY4405094: Administered Subcutaneously (SC)

Placebo: Administered IV

Placebo: Administered SC

Florbetapir F18: Administered IV

Florbetaben F 18: Administered IV

Study summary

The purpose of this study is to see how safe LY4405094 is and to see how much and how quickly LY4405094 gets into the bloodstream. For healthy participants, the study also looks at how much LY4405094 gets into the fluid around the brain and lasts up to 13 weeks and will include a 4-day stay in the Clinical Research Unit (CRU). For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 25 weeks and will include a 3-day stay in the CRU.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Participants must meet eligibility criteria in the ATMP screening protocol before entry into the treatment study. Exclusion Criteria: * Have known allergies to LY4405094, related compounds (including remternetug), or any components of the formulation, including LY4405094. * Have known allergic reactions to adhesive or hydrogels or a family history of adhesive skin allergies.

Primary outcome measure(s)

  • Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — Baseline up to 25 Weeks

Trial sites (16)

FacilityCityRegionStatus
CenExel ACT Anaheim California
Irvine Clinical Research Irvine California
Collaborative Neuroscience Network - CNS Los Alamitos California
Fortrea Clinical Research Unit Daytona Beach Florida
K2 Medical Research - The Villages Lady Lake Florida
K2 Medical Research Maitland Florida
Charter Research Orlando Florida
Progressive Medical Research Port Orange Florida
Alzheimer's Research and Treatment Center Stuart Florida
K2 Medical Research - Tampa Tampa Florida
Charter Research The Villages Florida
Accel Research Sites - NeuroStudies Clinical Research Unit Decatur Georgia
QUEST Research Institute Farmington Hills Michigan
Xuanwu Hospital Capital Medical University Beijing China
The University of Tokyo Hospital Bunkyō City Japan
National Center for Geriatrics and Gerontology Ōbu Japan

More Eli Lilly and Company trials in Japan

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) Active, not recruiting
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease Recruiting
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors Active, not recruiting
A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse Recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors Active, not recruiting

Other trials for the same condition

A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease Recruiting
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5) Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) Recruiting
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). Recruiting
Epidemiology and Biomarker Study in Alzheimer's Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07787182 on ClinicalTrials.gov ↗ ← All trials in Japan